Floatz Rating
B63/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00017147CT.gov S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Camustine (this asset) | SWOG Cancer Research Network | P3 | B · 63 |
| o6-benzylguanine | SWOG Cancer Research Network | P3 | B |
| Rvp-001 | Reveal Pharmaceuticals Inc. | P2 | B |
| Avapritinib | M.D. Anderson Cancer Center | P2 | CCC |
| TZ-3321 | Washington University School of Medicine | P2 | CCC |
| Ulixertinib | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Methadone | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P1 | CC |
+5 more in the Central Nervous System Cancer cohort
Other indications for Camustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Central Nervous System Neoplasm | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Camustine in Central Nervous System Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/camustine-central-nervous-system-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →